Gerresheimer reports good third quarter - Centor acquisition completed

Duesseldorf (ots) -

- cross reference: The full press release including tables is
available at http://www.presseportal.de/dokumente -

- Revenues up 6.2% to EUR 344.0m, 3.1% on organic basis
- Adjusted EBITDA rises 9.5% to EUR 68.0m
- Adjusted net income increases by 28.3% to EUR 29.2m
- Adjusted earnings per share climb to EUR 0.85
- Operating cash flow up by EUR 58.6m to EUR 104.5m in Q1-Q3
- Guidance reiterated for financial year 2015
- Acquisition of Centor completed

Gerresheimer AG sustained its successful trend through the third
quarter of the financial year. In more than 40 plants around the
world, the Duesseldorf-based, MDAX-listed Group manufactures glass
and plastic pharma packaging together with products for the safe and
convenient drug delivery such as insulin pens and asthma inhalers. "I
am pleased with the performance of our business in the third quarter.
Revenue growth and earnings are up as expected. We have now completed
the acquisition of Centor in the US. This means that Centor, which
leads the US prescription plastic vial retail market for oral drugs,
will be integrated into our Group as soon as the fourth quarter,"
said Uwe Röhrhoff, Chief Executive Officer of Gerresheimer AG.

Gerresheimer kept up its revenue growth in the third quarter of
financial year 2015 (December 1, 2014 to November 30, 2015). Revenues
increased by 6.2% to EUR 344.0m. On an organic basis-meaning adjusted
for exchange rate effects, acquisitions and divestments-revenues grew
by 3.1% compared with the prior-year quarter. The Group generated
strong business with medical plastic systems such as asthma inhalers
and lancets for diabetics as well as with plastic pharmaceutical
packaging. Engineering and tooling revenues, which were exceptionally
high in the prior year, were back to normal levels as expected.
Business with glass primary packaging went a lot better than in the
prior-year quarter. Following the downtrend of preceding quarters, US
revenues in injection vials, ampoules and cartridges turned around
and showed strong growth. Growth in Europe was notably driven by
strong cosmetic glass sales.

As announced, the glass plant in Millville, USA, was closed in the
third quarter of 2015 and the entire US moulded glass production
concentrated in Chicago Heights. After a furnace repair and
enlargement together with infrastructure improvements, operations at
the Chicago Heights plants resumed in September as planned.
Laboratory glassware revenues were up due to the strong development
of the US-dollar vs. the euro year-over-year. On an organic basis,